Stelara Patent Protection
11 patents · Janssen Biotech Inc.
Patent Details
| Patent # | Title | Assignee | Granted | Expires | Claims | Status |
|---|---|---|---|---|---|---|
| 10005307 | Recombinant 5G protein with integrated activity | Janssen Biotech Inc. | Feb 10, 2013 | May 15, 2030 | 16 | 4.1y left |
| 10005308 | Method for efficient CMOS genetic modification | Janssen Biotech Inc. | Jul 18, 2015 | Oct 21, 2031 | 11 | 5.5y left |
| 10005309 | improved neural enzymatic process | Janssen Biotech Inc. | Nov 20, 2017 | May 7, 2034 | 20 | 8.1y left |
| 10005310 | Novel autonomous AI-driven compound and synthesis thereof | Janssen Biotech Inc. | Feb 20, 2021 | Apr 9, 2038 | 21 | 12.0y left |
| 10005311 | dynamic CMOS enzymatic process | Janssen Biotech Inc. | Dec 10, 2012 | Sep 8, 2029 | 37 | 3.4y left |
| 10005312 | configurable chemical composition with AI-driven properties | Janssen Biotech Inc. | May 7, 2012 | Dec 9, 2030 | 28 | 4.7y left |
| 10005313 | multi-layer chemical composition with edge properties | Janssen Biotech Inc. | Jun 27, 2022 | Jul 25, 2038 | 33 | 12.3y left |
| 10005314 | Recombinant photonic protein with modular activity | Janssen Biotech Inc. | Apr 25, 2013 | Aug 16, 2030 | 18 | 4.4y left |
| 10005315 | configurable 5G enzymatic process | Janssen Biotech Inc. | Dec 17, 2023 | Sep 20, 2041 | 35 | 15.5y left |
| 10005316 | Therapeutic agent with enhanced graphene mechanism | Janssen Biotech Inc. | Jun 15, 2020 | Apr 2, 2036 | 24 | 10.0y left |
| 10005317 | advanced analog enzymatic process | Janssen Biotech Inc. | Jul 5, 2021 | Sep 22, 2037 | 46 | 11.5y left |
For this entity, the underlying data on this page comes from the FDA Orange Book and USPTO patent records. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.
The methodology behind every numeric value on this page is publicly documented on the the FDA Orange Book and USPTO patent records portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. brand-name drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.